- Trials with a EudraCT protocol (93)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
93 result(s) found for: Independent living.
Displaying page 1 of 5.
| EudraCT Number: 2005-000381-39 | Sponsor Protocol Number: KCL/DS/MEM/1 | Start Date*: 2005-08-24 |
| Sponsor Name:King's College London | ||
| Full Title: Efficacy and Safety of Memantine Hydrochloride, a low affinity antagonist to N-Methyl-D-Aspartate (NMDA) type receptors, in the prevention of cognitive decline and disease progression in older peop... | ||
| Medical condition: Cognitive decline and dementia in Down's syndrome | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2010-023888-17 | Sponsor Protocol Number: OMS103-MEN-003 | Start Date*: 2011-05-11 | |||||||||||
| Sponsor Name:Omeros Corporation | |||||||||||||
| Full Title: A Randomized, Double-Blind, Parallel Group, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic ... | |||||||||||||
| Medical condition: Arthroscopic surgery | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-014424-29 | Sponsor Protocol Number: H6L-MC-LFBF (b) | Start Date*: 2010-02-05 |
| Sponsor Name:Eli Lilly and Company | ||
| Full Title: Open-Label Extension for Alzheimer’s Disease Patients Who Complete One of Two Semagacestat Phase 3 Double-Blind Studies (H6L-MC-LFAN or H6L-MC-LFBC) | ||
| Medical condition: Alzheimer's Disease | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FI (Completed) DE (Completed) ES (Prematurely Ended) BE (Completed) IT (Completed) FR (Completed) SE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2004-000502-40 | Sponsor Protocol Number: RHM CAN0380 | Start Date*: 2005-05-13 |
| Sponsor Name:Southampton University Hospitals Trust | ||
| Full Title: A thematic analysis of semi-structured interviews using a phenomenological approach into palliative care patients experiences of change in "fatigue" following treatment with methylphenidate – an ex... | ||
| Medical condition: Patients with cancer in palliative stage of their illness. Suffering from fatigue with or without decreased concentration, depression or drowsiness, who feel their fatigue is severe enough to decre... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (GB - no longer in EU/EEA) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-000095-10 | Sponsor Protocol Number: BATCP | Start Date*: 2015-03-30 |
| Sponsor Name:Karolinska Institutet | ||
| Full Title: Botulinum toxin-A as a treatment for chronic muscle-related pain in adults with spastic cerebral palsy: a randomized controlled trial. | ||
| Medical condition: Spastic cerebral palsy | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2009-017925-20 | Sponsor Protocol Number: RR08/8789 | Start Date*: 2010-09-07 | ||||||||||||||||
| Sponsor Name:University of Leeds | ||||||||||||||||||
| Full Title: Does Cocareldopa treatment in combination with routine NHS occupational and physical therapy, delivered early after stroke within a stroke service, improve functional recovery including walking and... | ||||||||||||||||||
| Medical condition: Ischaemic or Haemorrhagic Stroke | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2019-001730-34 | Sponsor Protocol Number: TX200-KT02 | Start Date*: 2020-03-24 | |||||||||||
| Sponsor Name:Sangamo Therapeutics France SAS | |||||||||||||
| Full Title: A Multicentre, Open-Label, Single Ascending Dose, Dose-Ranging, Phase I/IIa Study to Evaluate the Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Ce... | |||||||||||||
| Medical condition: Prevention of immune mediated allograft rejection in patients with end-stage renal disease (ESRD) who are tissue typed as HLA-A*02 negative and have received a kidney transplant from an HLA-A*02 po... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) NL (Trial now transitioned) DE (Completed) BE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2007-007134-19 | Sponsor Protocol Number: GAM10-04 | Start Date*: 2009-01-14 |
| Sponsor Name:Octapharma AG | ||
| Full Title: Prospective 24-week, double-blind, randomized, placebo-controlled, multicenter study evaluating safety and change in efficacy-related surrogate parameters in patients with dementia of the Alzheimer... | ||
| Medical condition: mild to moderate Alzheimer´s disease | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2020-002360-30 | Sponsor Protocol Number: NA-1-009 | Start Date*: 2021-01-05 | |||||||||||||||||||||||||||||||
| Sponsor Name:NoNO Inc. | |||||||||||||||||||||||||||||||||
| Full Title: A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Nerinetide in Participants with Acute Ischemic Stroke Under... | |||||||||||||||||||||||||||||||||
| Medical condition: Acute ischemic stroke (AIS) | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) NO (Prematurely Ended) IT (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2016-002347-41 | Sponsor Protocol Number: CA209-744 | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
| Full Title: Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin... | |||||||||||||
| Medical condition: Relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL) | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) ES (Ongoing) IE (Completed) DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) PL (Completed) Outside EU/EEA IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-004719-28 | Sponsor Protocol Number: D8850C00003 | Start Date*: 2020-11-20 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 a... | |||||||||||||
| Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-003192-19 | Sponsor Protocol Number: ISRCTN11225767 | Start Date*: 2013-02-22 | |||||||||||
| Sponsor Name:London School Of Hygiene and Tropical Medicine | |||||||||||||
| Full Title: Tranexamic acid for the treatment of gastrointestinal haemorrhage: an international randomised, double blind placebo controlled trial | |||||||||||||
| Medical condition: Gastrointestinal hemorrhage | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) RO (Completed) ES (Prematurely Ended) IE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-000717-31 | Sponsor Protocol Number: WI187847 | Start Date*: 2015-06-09 | |||||||||||
| Sponsor Name:UZ Leuven | |||||||||||||
| Full Title: A randomised, double-blind, placebo-controlled study of celecoxib after collagenase injection for adults with Dupuytren’s disease at high risk of recurrence | |||||||||||||
| Medical condition: Dupuytren's disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-001677-31 | Sponsor Protocol Number: AMB-001 | Start Date*: 2022-10-28 | |||||||||||
| Sponsor Name:Aarhus University Hospital | |||||||||||||
| Full Title: Administration of the BCL-2 antagonist, venetoclax, to promote apoptosis of HIV-infected cells and reduce the size of the HIV reservoir: An investigator-initiated phase I/IIb clinical trial in peop... | |||||||||||||
| Medical condition: HIV-1 infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-002530-20 | Sponsor Protocol Number: GEM-1802 | Start Date*: 2019-03-12 | ||||||||||||||||
| Sponsor Name:Grupo Español Multidisciplinar de Melanoma | ||||||||||||||||||
| Full Title: Multicentric phase II clinical trial to evaluate the activity of encorafenib and binimetinib before local treatment in patients with BRAF mutated melanoma with metastasis to the brain. | ||||||||||||||||||
| Medical condition: BRAF mutant melanoma metastatic to the brain | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: ES (Ongoing) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2012-001447-43 | Sponsor Protocol Number: ALIFE2 | Start Date*: 2018-10-03 | |||||||||||
| Sponsor Name:Academic Medical Center Amsterdam | |||||||||||||
| Full Title: Anticoagulants for Living Fetuses in women with recurrent miscarriage and inherited thrombophilia; ALIFE2 study | |||||||||||||
| Medical condition: recurrent miscarriage and inherited thrombophilia | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: AT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2004-004209-98 | Sponsor Protocol Number: PEP 1.05 | Start Date*: 2005-12-08 |
| Sponsor Name:Medical University Vienna, Department of Medicine III | ||
| Full Title: The Vienna Prograf and Endothelial Progenitor Cell Study (Vienna PEP Study) | ||
| Medical condition: Kidney Transplantation | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2011-006201-10 | Sponsor Protocol Number: REP0211 | Start Date*: 2012-08-13 | |||||||||||
| Sponsor Name:Dompé s.p.a. | |||||||||||||
| Full Title: A phase 3, multicenter, randomized, double-blind, parallel assignment study to assess the efficacy and safety of reparixin in pancreatic islet transplantation | |||||||||||||
| Medical condition: Pancreatic islet transplantation | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) GB (Completed) SE (Prematurely Ended) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-004946-27 | Sponsor Protocol Number: E2020-A001-219 | Start Date*: 2017-05-18 |
| Sponsor Name:Eisai Inc. | ||
| Full Title: A 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With D... | ||
| Medical condition: Down Syndrome, Cognitive Dysfunction | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2015-003395-72 | Sponsor Protocol Number: VitD@BPPV | Start Date*: 2016-11-29 |
| Sponsor Name:Hospital of the University of Munich | ||
| Full Title: Vitamin D in secondary prevention of benign paroxysmal positional vertigo: a prospective, multicenter, randomized, placebo-controlled, double-blind study (VitD@BPPV) | ||
| Medical condition: The main symptoms of Benign Paroxysmal Positional Vertigo (BPPV) are brief, in part strong attacks of rotatory vertigo lasting seconds. These attacks can be provoked by reclination of the head or t... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.